All In Biotech

Drug Trial Radar · NCT01153672

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Nov 2010

Primary completion

Jul 2012

Study completion Aug 11, 2016

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug

Conditions

  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer

Interventions

  • vorinostatDrug

    Given PO

  • laboratory biomarker analysisOther

    Correlative studies

  • biopsyProcedure

    Optional correlative studies

  • F-18 16 alpha-fluoroestradiolRadiation

    Correlative studies

  • positron emission tomographyProcedure

    Correlative studies

  • anastrozoleDrug

    Given PO

  • letrozoleDrug

    Given PO

  • exemestaneDrug

    Given PO

  • gene expression analysisGenetic

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Clinical Benefit According to RECISTTime frame: Up to approximately 5 years
  2. Duration of ResponseTime frame: Up to approximately 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.